Ermium Therapeutics, a Paris, France-based biotech company, raised €6.3M in funding, bringing total funding to date to €12.3m.
The round was led by Kurma Partners and Fountain Healthcare Partners.
The company intends to use them funds to reach the milestones of drug candidate selection, extend the non-clinical development package, and drive continued efforts on the pharmacological package in support of the early clinical development program in SLE and other auto-immune diseases.
founded in June 2019 by Dr Jean-Philippe Herbeuval (CNRS – Université Paris Cité), Kurma Partners, Domain Therapeutics, and Erganeo and led by CEO Joël Crouzet, Ermium Therapeutics is a discovery stage company developing small molecules, orally available, that are aimed at addressing a range of chronic auto-immune diseases, affecting millions of people worldwide, and particularly type I interferon-mediated diseases such as systemic lupus erythematosus (SLE), dermatomyositis, Sjögren syndrome, and monogenic interferonopathies. Its proprietary compounds are intended to be first-in-class acting on a well-known G protein-coupled receptor (GPCR), namely the CXCR4 chemokine receptor, via a totally novel mechanism of action. The main property of Ermium CXCR4-targeted functionally selective immunomodulators is to potently abolish the release of type I interferons by immune cells, and also other key inflammatory cytokines.
Ermium Therapeutics is based at the Paris Biotech Santé Incubator – Accelerator located at the Cochin Hospital in Paris. The company has signed a worldwide exclusive license agreement on intellectual property from the CNRS and the Université Paris Cité through an agreement with Erganeo.